{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:12:35Z","timestamp":1791360755863,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL159156"],"award-info":[{"award-number":["R01 HL159156"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL170224"],"award-info":[{"award-number":["HL170224"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.atherosclerosis.2025.120469","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:39:30Z","timestamp":1754415570000},"page":"120469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumab"],"prefix":"10.1016","volume":"409","author":[{"given":"Mark","family":"Atallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Gerstenblith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2569-6617","authenticated-orcid":false,"given":"Thorsten M.","family":"Leucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120469_bib1","article-title":"Heart disease and stroke statistics: a report of US and global data from the American heart association","volume":"2025","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized phospholipids in cardiovascular disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/bmm.11.60","article-title":"Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events","volume":"5","author":"Taleb","year":"2011","journal-title":"Biomarkers Med"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib6","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.jacc.2013.02.047","article-title":"Oxidation-specific biomarkers and risk of peripheral artery disease","volume":"61","author":"Bertoia","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib7","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib8","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","article-title":"Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes","volume":"81","author":"Gilliland","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race\/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas heart study","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in acute myocardial infarction: the good, the bad and the ugly","volume":"45","author":"Matter","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the Peri- and early postinfarction period: a Placebo-Controlled, randomized trial","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","article-title":"The trajectory of Lipoprotein(a) during the Peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/Kexin type 9 inhibition","volume":"171","author":"Vavuranakis","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib14","doi-asserted-by":"crossref","first-page":"oead035","DOI":"10.1093\/ehjopen\/oead035","article-title":"Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up","volume":"3","author":"Ziogos","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial","volume":"65","author":"Byun","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2021.07.031","article-title":"PCSK9 inhibition and oxidized phospholipids","volume":"78","author":"Bhatia","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib18","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and Lipoprotein(a)","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.carrev.2011.08.001","article-title":"The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization","volume":"13","author":"Fefer","year":"2012","journal-title":"Cardiovasc Revascularization Med Mol Interv"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0735-1097(02)02769-9","article-title":"Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes","volume":"41","author":"Tsimikas","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib21","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jacc.2014.01.055","article-title":"Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans","volume":"63","author":"Ravandi","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/cvr\/cvy136","article-title":"Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids","volume":"115","author":"Yeang","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034774","article-title":"Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the CASABLANCA study","volume":"13","author":"Januzzi","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOL.0b013e328308b622","article-title":"The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity","volume":"19","author":"Tsimikas","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib25","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2024.08.070","article-title":"Oxidized phospholipids and calcific aortic valvular disease","volume":"84","author":"Bhatia","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacc.2016.10.057","article-title":"Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack","volume":"69","author":"Byun","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib27","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, Lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib28","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"JACC"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.5433","article-title":"Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers: results from the OCEAN(a)-DOSE trial","author":"Rosenson","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5551\/jat.63549","article-title":"Relationship between serum proprotein convertase subtilisin\/Kexin type 9 concentration and prevalence of coronary artery calcium in a community-based sample of Japanese men","volume":"30","author":"Kunimura","year":"2023","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib33","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1194\/jlr.P119000173","article-title":"PCSK9 loss-of-function variants and lp(a) phenotypes among black US adults","volume":"60","author":"Mefford","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib36","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib37","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120469_bib38","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502501367X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502501367X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:53:35Z","timestamp":1772790815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502501367X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"alternative-id":["S002191502501367X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120469","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumab","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120469"}}